Crohn's Disease Activity Index

From WikiMD's WELLNESSPEDIA

Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It was developed in the 1970s by Dr. William Best and his colleagues to provide a standardized measure of disease activity and to track changes over time.

Overview[edit]

The CDAI is a composite score that includes eight variables: the number of liquid or very soft stools, the severity of abdominal pain, general well-being, the presence of extraintestinal symptoms, the need for anti-diarrheal medication, the presence of abdominal mass, hematocrit levels, and deviations from ideal weight. Each variable is assigned a weighted score, which are then summed to give a total score. A higher score indicates more severe disease activity.

Calculation[edit]

The CDAI score is calculated using the following formula:

CDAI = (2 x number of liquid or very soft stools) + (5 x abdominal pain score) + (7 x general well-being score) + (20 x presence of extraintestinal symptoms) + (10 x use of anti-diarrheal medication) + (30 x presence of abdominal mass) + (6 x (ideal hematocrit - actual hematocrit)) + (1 x (ideal weight - actual weight))

Interpretation[edit]

A CDAI score of less than 150 is considered remission, a score of 150-220 indicates mild disease, a score of 220-450 indicates moderate disease, and a score of more than 450 indicates severe disease.

Limitations[edit]

While the CDAI is widely used in clinical trials and research, it has several limitations. It is subjective, as it relies on patient-reported symptoms, and it may not accurately reflect the severity of inflammation or damage in the intestines. Furthermore, it does not include some important aspects of the disease, such as the impact on quality of life or the presence of fistulas or abscesses.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.